Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
GlobeNewswire
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024;..
ATPase
News and Video Search Results
News coverage
-
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
GlobeNewswire
-
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
GlobeNewswire
-
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
GlobeNewswire
-
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
GlobeNewswire
0 shares
1 views
You might like
ATPase media coverage
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
GlobeNewswire
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first..
-
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
GlobeNewswire
-
Windtree Therapeutics Announces Reduction In Arrhythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
Upworthy
-
Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
GlobeNewswire
-
Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis
GlobeNewswire
Advertisement
More coverage
Revolo Biotherapeutics Presents New Data on ‘1805 at the American College of Rheumatology Convergence 2023 Annual Conference
GlobeNewswire
- New preclinical data further elucidate ‘1805’s mechanism of action in rheumatoid arthritis (RA) -
NEW ORLEANS and..
-
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
GlobeNewswire
-
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
GlobeNewswire
-
Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office
GlobeNewswire
-
Unwinding the world's smallest biological rotary motor by degrees
Science Daily